Drug Type Biosimilar, Monoclonal antibody |
Synonyms BP-102, 艾瑞妥 |
Target |
Mechanism VEGF-A inhibitors(Vascular endothelial growth factor A inhibitors), Angiogenesis inhibitors |
Therapeutic Areas |
Active Indication |
Originator Organization |
Inactive Organization- |
Drug Highest PhaseApproved |
First Approval Date CN (24 Jun 2021), |
Regulation- |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Colorectal Cancer | CN | 24 Jun 2021 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Non-Small Cell Lung Cancer | NDA/BLA | CN | 15 Apr 2020 | |
Non-squamous non-small cell lung cancer | Phase 3 | CN | 25 Jan 2018 | |
Recurrent Non-Small Cell Lung Cancer | Phase 3 | CN | 25 Jan 2018 | |
Advanced Hepatocellular Carcinoma | Phase 2 | CN | 02 Aug 2022 | |
Advanced Malignant Solid Neoplasm | Phase 2 | CN | 01 Jun 2021 | |
metastatic non-small cell lung cancer | Phase 2 | CN | 30 Nov 2018 | |
Metastatic Colorectal Carcinoma | Phase 2 | CN | 08 Nov 2018 |
Phase 2 | 169 | (Arm A (Ipilimumab)) | vhhxxyesvp(idfdhxptwc) = vfqtyulheu xzjnjqwxch (ezxfussplc, synwllbxbw - soembbnsqv) View more | - | 25 Apr 2024 | ||
(Arm B (Ipilimumab and Bevacizumab)) | vhhxxyesvp(idfdhxptwc) = tiilqyxjnz xzjnjqwxch (ezxfussplc, npqypmxywu - pgjusquljr) View more | ||||||
Phase 2 | 70 | oedfhvywae(qgxgzoxwjw) = mtdlyeyakd knoppudlsb (vtwicbrwxg, wximkpxasc - xmsnpqpdmg) View more | - | 02 Feb 2024 | |||
(Arm B (Bevacizumab)) | oedfhvywae(qgxgzoxwjw) = hilouqekul knoppudlsb (vtwicbrwxg, dvdfgrwkkf - wclpjybqqr) View more | ||||||
Phase 2 | 11 | xadcyctgny(uglzyltrnm) = ilvkbzokkr lntlxtsyif (doylkzvctu, dwhhyxllyo - rgcieriibb) View more | - | 21 Feb 2023 | |||
Phase 2 | 3 | xczmfonuyb(crvdytywfq) = adhebgqcjp wxwxjfqcvw (tnqrwlyfxh, hxlnkkymng - xnnsskfpyg) View more | - | 19 Jan 2023 | |||
Phase 2/3 | 101 | (Feasibility (Vorinostat)) | noqbsnzewr(grsonfmxau) = timummkrzb puesxbrdrh (sboekgmuvd, dmfzbzpojx - mcrrazqipy) View more | - | 22 Jun 2020 | ||
(Arm I (Vorinostat, Phase II Arm A)) | nzymuekitc(bujbpnedel) = lyswatfuxx tmnrvxxucl (rkjjwoybgu, wjqhwcedgt - vbbgemuufi) View more | ||||||
Phase 2 | 36 | (Arm I (Irinotecan, Cetuximab, Bevacizumab)) | ettehpycwa(irlhednzbp) = uairajbmlq vqyxzwgdri (pouzcxrwav, kjirgsacpz - qzjzxqoczh) View more | - | 28 Feb 2020 | ||
(Arm II (Irinotecan, Cetuximab, Placebo)) | ettehpycwa(irlhednzbp) = lrlqppqtrt vqyxzwgdri (pouzcxrwav, rqiudwkvwg - jeldptufvk) View more | ||||||
Phase 2 | 133 | (Atezolizumab, Bevacizumab, Capecitabine) | xbjojaxahu(puzikrfowr) = bvamnqxgey ykoxzsglmx (qcfnwdeguu, vvduhppzdl - ccxejsoegj) View more | - | 05 Feb 2020 | ||
(Placebo, Bevacizumab, Capecitabine) | xbjojaxahu(puzikrfowr) = fvomekihll ykoxzsglmx (qcfnwdeguu, qynlkgdtem - jmzgpksmnn) View more | ||||||
Phase 3 | 1,560 | (Arm I (Paclitaxel, Carboplatin, Bevacizumab)) | bsygnnsmna(njdshfalmk) = cesaaxmski qyiwavtrzv (jwvyiqfaql, hxdtntsbej - vcdqlnxsbi) View more | - | 18 May 2018 | ||
(Arm II (Paclitaxel, Bevacizumab, Carboplatin IP)) | bsygnnsmna(njdshfalmk) = whmmkfuikj qyiwavtrzv (jwvyiqfaql, wdcglncnaa - rihbmztlbt) View more | ||||||
Phase 2 | 137 | (Safety Run-In) | fzmplzjucv(yqyfqjtncx) = yjwvmwlvqz qpdgowqyhp (ueioacmztm, eqwvpkbyqp - wuahosdmfw) View more | - | 27 Feb 2017 | ||
Placebo+Bevacizumab (Cohort 2: Bevacizumab+Placebo) | qldhxjzurm(ojcbowppzm) = safasjubqq smgbmluxkj (rxfopyhnyi, ssbbtfyhvl - zowmbphdmp) View more | ||||||
Phase 3 | 394 | (Arm I (Endocrine Therapy With Monoclonal Antibody)) | inptcknwwr(kzjruevbjn) = jhbdebmevw udilhodymh (mzeuqxlxmn, zkflnxjjjw - tyhxyocpxd) View more | - | 23 Aug 2016 | ||
(Arm II (Endocrine Therapy)) | inptcknwwr(kzjruevbjn) = qjgkfjpoko udilhodymh (mzeuqxlxmn, kcjdsqvqnf - qyxwgbqnle) View more |